patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_875518 | REC_0014101 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 2.5 | 72 | female | 2 | 15 | 7.9 | 1 | sotorasib 960 mg daily | 18.9 | false | MSS | 2026-03-15T05:36:00.647595+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816487 | REC_0014102 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 13.8 | 71 | female | 2 | 21 | 5.7 | 1 | osimertinib 80 mg daily | 16.6 | false | MSS | 2026-03-15T05:36:00.647986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572032 | REC_0014103 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 15.3 | 67 | female | 1 | 15 | 5.7 | 4 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:36:00.648399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916452 | REC_0014104 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 6.9 | 68 | male | 1 | 13 | 4.2 | 7 | sotorasib 960 mg daily | 5.5 | true | MSS | 2026-03-15T05:36:00.648772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934739 | REC_0014105 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 10.8 | 60 | male | 1 | 13 | 7 | 6 | osimertinib 80 mg daily | 6.4 | true | MSI-H | 2026-03-15T05:36:00.649119+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138990 | REC_0014106 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 10 | 62 | male | 0 | 16 | 7.6 | 1 | osimertinib 80 mg daily | 10.3 | false | MSS | 2026-03-15T05:36:00.649609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826501 | REC_0014107 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 5.8 | 68 | female | 1 | 17 | 4.7 | 5 | osimertinib 80 mg daily | 8.2 | true | MSS | 2026-03-15T05:36:00.649979+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184046 | REC_0014108 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 16.2 | 61 | female | 0 | 21 | 4.8 | 1 | osimertinib 80 mg daily | 22.8 | true | MSS | 2026-03-15T05:36:00.650314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499028 | REC_0014109 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 13.4 | 73 | female | 2 | 15 | 4.3 | 1 | alectinib 600 mg BID | 17.6 | true | MSI-H | 2026-03-15T05:36:00.650661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252404 | REC_0014110 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 30 | 10.4 | 75 | female | 1 | 4 | 8.2 | 0 | osimertinib 80 mg daily | 55.5 | false | MSS | 2026-03-15T05:36:00.650999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730403 | REC_0014111 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 9.7 | 73 | female | 1 | 17 | 4.2 | 2 | entrectinib 600 mg daily | 29.3 | true | MSS | 2026-03-15T05:36:00.651310+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_663342 | REC_0014112 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 7 | 69 | female | 1 | 26 | 4 | 7 | osimertinib 80 mg daily | 8.2 | true | MSS | 2026-03-15T05:36:00.651621+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801192 | REC_0014113 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 9 | 50 | male | 0 | 10 | 6.5 | 8 | osimertinib 80 mg daily | 9 | false | MSS | 2026-03-15T05:36:00.651936+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708423 | REC_0014114 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 10.3 | 59 | male | 0 | 15 | 4.6 | 2 | sotorasib 960 mg daily | 18.7 | false | MSI-H | 2026-03-15T05:36:00.652374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229699 | REC_0014115 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.3 | 74 | female | 1 | 74 | 5.7 | 8 | carboplatin + paclitaxel + pembrolizumab | 9.5 | true | MSS | 2026-03-15T05:36:00.652730+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269711 | REC_0014116 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 3.8 | 65 | female | 1 | 9 | 6.3 | 3 | pembrolizumab 200 mg q3w | 19.1 | false | MSS | 2026-03-15T05:36:00.653028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159894 | REC_0014117 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 8 | 70 | female | 2 | 11 | 5.4 | 5 | osimertinib 80 mg daily | 13.1 | true | MSS | 2026-03-15T05:36:00.653316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411249 | REC_0014118 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 13 | 72 | female | 2 | 13 | 7.5 | 2 | sotorasib 960 mg daily | 20 | true | MSS | 2026-03-15T05:36:00.653620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862591 | REC_0014119 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.7 | 66 | female | 1 | 13 | 5 | 7 | osimertinib 80 mg daily | 13.5 | false | MSS | 2026-03-15T05:36:00.654139+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984563 | REC_0014120 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 13.1 | 76 | female | 2 | 23 | 6.9 | 6 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:00.654503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608148 | REC_0014121 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 6 | 81 | male | 2 | 7 | 7 | 5 | osimertinib 80 mg daily | 10 | false | MSS | 2026-03-15T05:36:00.654816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_775069 | REC_0014122 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 12.1 | 70 | male | 2 | 18 | 7.4 | 1 | osimertinib 80 mg daily | 21.1 | true | MSS | 2026-03-15T05:36:00.655118+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792623 | REC_0014123 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 11.4 | 48 | male | 0 | 3 | 4.8 | 3 | osimertinib 80 mg daily | 16.4 | true | MSS | 2026-03-15T05:36:00.655415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_595585 | REC_0014124 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 10.4 | 67 | female | 1 | 24 | 4 | 4 | sotorasib 960 mg daily | 12.1 | true | MSS | 2026-03-15T05:36:00.655706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907809 | REC_0014125 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.6 | 71 | male | 1 | 23 | 5.4 | 7 | alectinib 600 mg BID | 10.4 | false | MSI-H | 2026-03-15T05:36:00.656005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948148 | REC_0014126 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 13.8 | 63 | female | 1 | 26 | 2.8 | 1 | sotorasib 960 mg daily | 21.1 | false | MSS | 2026-03-15T05:36:00.656391+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_576824 | REC_0014127 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 12.1 | 77 | male | 2 | 13 | 7.6 | 8 | osimertinib 80 mg daily | 14.8 | true | MSS | 2026-03-15T05:36:00.656734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840498 | REC_0014128 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 16 | 5.7 | 55 | female | 1 | 25 | 5 | 2 | pembrolizumab 200 mg q3w | 20.5 | false | MSS | 2026-03-15T05:36:00.657044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_258506 | REC_0014129 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 10.8 | 64 | female | 0 | 5 | 7.2 | 6 | osimertinib 80 mg daily | 10.3 | false | MSS | 2026-03-15T05:36:00.657360+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476199 | REC_0014130 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 9.5 | 77 | female | 1 | 16 | 4.5 | 1 | sotorasib 960 mg daily | 13.2 | true | MSS | 2026-03-15T05:36:00.657683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812630 | REC_0014131 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 23 | 3.6 | 65 | male | 1 | 34 | 5.1 | 0 | carboplatin + paclitaxel + pembrolizumab | 38.8 | false | MSS | 2026-03-15T05:36:00.658001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173022 | REC_0014132 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 3.8 | 60 | female | 1 | 52 | 5.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.7 | true | MSS | 2026-03-15T05:36:00.658520+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237594 | REC_0014133 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 15 | 7.5 | 80 | female | 1 | 62 | 2.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.8 | true | MSS | 2026-03-15T05:36:00.658865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_526959 | REC_0014134 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 9.9 | 69 | female | 0 | 16 | 4.2 | 2 | entrectinib 600 mg daily | 15.7 | false | MSS | 2026-03-15T05:36:00.659207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698452 | REC_0014135 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 10.6 | 54 | female | 0 | 18 | 6.8 | 1 | sotorasib 960 mg daily | 22.1 | true | MSS | 2026-03-15T05:36:00.659575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140790 | REC_0014136 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 9 | 69 | female | 0 | 6 | 5.1 | 1 | sotorasib 960 mg daily | 20.1 | false | MSS | 2026-03-15T05:36:00.659899+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175511 | REC_0014137 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11.8 | 66 | female | 0 | 20 | 5.5 | 6 | sotorasib 960 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:36:00.660305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_261372 | REC_0014138 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 18.2 | 63 | male | 0 | 16 | 6.2 | 1 | sotorasib 960 mg daily | 29.1 | true | MSI-H | 2026-03-15T05:36:00.660685+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_582164 | REC_0014139 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 7.8 | 56 | male | 0 | 8 | 3.9 | 2 | entrectinib 600 mg daily | 20.3 | false | MSS | 2026-03-15T05:36:00.661009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542932 | REC_0014140 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 14.9 | 49 | female | 0 | 11 | 2.6 | 3 | sotorasib 960 mg daily | 4 | false | MSI-H | 2026-03-15T05:36:00.661339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722869 | REC_0014141 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 30 | 6.6 | 61 | male | 1 | 8 | 4.6 | 2 | pembrolizumab 200 mg q3w | 14.1 | true | MSS | 2026-03-15T05:36:00.661651+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_382934 | REC_0014142 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 2.9 | 82 | male | 1 | 2 | 5.9 | 1 | pembrolizumab 200 mg q3w | 21.5 | false | MSS | 2026-03-15T05:36:00.661987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383283 | REC_0014143 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 15 | 8.4 | 78 | female | 1 | 20 | 6.4 | 5 | osimertinib 80 mg daily | 15.6 | false | MSS | 2026-03-15T05:36:00.662333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149631 | REC_0014144 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 15 | 9.1 | 67 | female | 0 | 20 | 6.6 | 4 | osimertinib 80 mg daily | 10.9 | false | MSS | 2026-03-15T05:36:00.662654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105143 | REC_0014145 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 14.7 | 81 | female | 2 | 20 | 3 | 5 | osimertinib 80 mg daily | 18.1 | false | MSI-H | 2026-03-15T05:36:00.663131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_273674 | REC_0014146 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 11.8 | 64 | female | 1 | 18 | 4.7 | 1 | entrectinib 600 mg daily | 16.6 | true | MSI-H | 2026-03-15T05:36:00.663516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493906 | REC_0014147 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 19.8 | 61 | male | 1 | 8 | 5.6 | 5 | sotorasib 960 mg daily | 20.8 | true | MSI-H | 2026-03-15T05:36:00.663975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848544 | REC_0014148 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 10.4 | 63 | male | 1 | 23 | 4.5 | 7 | osimertinib 80 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:36:00.664421+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508573 | REC_0014149 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 12.2 | 50 | female | 0 | 20 | 6.5 | 5 | pembrolizumab 200 mg q3w | 13.6 | false | MSI-H | 2026-03-15T05:36:00.664820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_902114 | REC_0014150 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 17.6 | 55 | female | 0 | 14 | 5.6 | 2 | alectinib 600 mg BID | 13 | true | MSI-H | 2026-03-15T05:36:00.665199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800320 | REC_0014151 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 12.6 | 73 | female | 0 | 16 | 8.6 | 2 | osimertinib 80 mg daily | 22.5 | false | MSI-H | 2026-03-15T05:36:00.665562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371945 | REC_0014152 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 8.6 | 75 | female | 1 | 8 | 5.3 | 4 | sotorasib 960 mg daily | 4.8 | false | MSS | 2026-03-15T05:36:00.665922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535290 | REC_0014153 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 7.4 | 72 | female | 2 | 13 | 4.3 | 3 | osimertinib 80 mg daily | 6.2 | false | MSS | 2026-03-15T05:36:00.666281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459959 | REC_0014154 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 6.8 | 74 | female | 2 | 20 | 5.6 | 2 | entrectinib 600 mg daily | 27.4 | false | MSS | 2026-03-15T05:36:00.666602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210792 | REC_0014155 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 11.1 | 65 | male | 1 | 0 | 6.9 | 6 | entrectinib 600 mg daily | 11 | false | MSS | 2026-03-15T05:36:00.666925+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847851 | REC_0014156 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12 | 72 | female | 1 | 25 | 4.7 | 7 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:36:00.667280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839884 | REC_0014157 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 16.6 | 69 | male | 1 | 19 | 5.6 | 4 | alectinib 600 mg BID | 14.2 | false | MSS | 2026-03-15T05:36:00.667623+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265947 | REC_0014158 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 32 | 4.8 | 49 | male | 0 | 16 | 4.5 | 1 | pembrolizumab 200 mg q3w | 5.7 | false | MSS | 2026-03-15T05:36:00.668210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633171 | REC_0014159 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.9 | 70 | male | 2 | 44 | 5.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.8 | true | MSS | 2026-03-15T05:36:00.668616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309099 | REC_0014160 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 14.8 | 64 | male | 0 | 0 | 3.4 | 8 | sotorasib 960 mg daily | 16.7 | true | MSI-H | 2026-03-15T05:36:00.668929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158746 | REC_0014161 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 16.1 | 67 | female | 1 | 23 | 5.5 | 4 | osimertinib 80 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:36:00.669248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550979 | REC_0014162 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 16.2 | 64 | male | 1 | 19 | 2 | 5 | sotorasib 960 mg daily | 9.1 | false | MSS | 2026-03-15T05:36:00.669570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_308734 | REC_0014163 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 8 | 74 | female | 2 | 16 | 4.9 | 1 | osimertinib 80 mg daily | 11.1 | true | MSS | 2026-03-15T05:36:00.669895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742698 | REC_0014164 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 15 | 15 | 57 | male | 0 | 10 | 4.9 | 1 | sotorasib 960 mg daily | 21.7 | false | MSS | 2026-03-15T05:36:00.670387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940019 | REC_0014165 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 9.1 | 51 | female | 0 | 0 | 6.7 | 3 | carboplatin + paclitaxel + pembrolizumab | 10.8 | true | MSS | 2026-03-15T05:36:00.670753+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_455399 | REC_0014166 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.2 | 61 | male | 0 | 24 | 6 | 5 | alectinib 600 mg BID | 11.8 | false | MSS | 2026-03-15T05:36:00.671092+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_490420 | REC_0014167 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 12.6 | 54 | female | 0 | 11 | 5.8 | 2 | alectinib 600 mg BID | 26 | true | MSS | 2026-03-15T05:36:00.671425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362698 | REC_0014168 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 4.1 | 67 | female | 0 | 42 | 2.9 | 3 | pembrolizumab 200 mg q3w | 15.9 | true | MSS | 2026-03-15T05:36:00.671747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_196448 | REC_0014169 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 10.7 | 60 | female | 1 | 16 | 4.7 | 6 | entrectinib 600 mg daily | 9.9 | false | MSI-H | 2026-03-15T05:36:00.672134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_479254 | REC_0014170 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 6.4 | 49 | female | 0 | 30 | 5.8 | 8 | pembrolizumab 200 mg q3w | 19 | true | MSS | 2026-03-15T05:36:00.672494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_388455 | REC_0014171 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 16.2 | 73 | female | 1 | 22 | 5.2 | 2 | sotorasib 960 mg daily | 13.3 | false | MSS | 2026-03-15T05:36:00.673000+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420390 | REC_0014172 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13 | 68 | male | 1 | 23 | 5.6 | 6 | osimertinib 80 mg daily | 10.7 | true | MSI-H | 2026-03-15T05:36:00.673379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429360 | REC_0014173 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 34 | 2.7 | 62 | male | 0 | 20 | 5.9 | 1 | osimertinib 80 mg daily | 20.3 | false | MSS | 2026-03-15T05:36:00.673723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288625 | REC_0014174 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 4.2 | 62 | female | 1 | 19 | 6.4 | 6 | entrectinib 600 mg daily | 9.5 | true | MSS | 2026-03-15T05:36:00.674057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317449 | REC_0014175 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 15 | 16.5 | 56 | male | 0 | 17 | 4.7 | 1 | alectinib 600 mg BID | 17.7 | true | MSI-H | 2026-03-15T05:36:00.674417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_481631 | REC_0014176 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 9.3 | 67 | female | 1 | 14 | 5.4 | 2 | alectinib 600 mg BID | 18.8 | false | MSS | 2026-03-15T05:36:00.674755+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_530871 | REC_0014177 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 3.7 | 70 | female | 3 | 49 | 3.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.8 | true | MSS | 2026-03-15T05:36:00.675099+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_418426 | REC_0014178 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 7.4 | 67 | female | 1 | 15 | 4.8 | 8 | osimertinib 80 mg daily | 15.6 | false | MSS | 2026-03-15T05:36:00.675427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687079 | REC_0014179 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 9.6 | 84 | male | 2 | 13 | 4 | 1 | osimertinib 80 mg daily | 19.9 | false | MSS | 2026-03-15T05:36:00.675785+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641585 | REC_0014180 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5 | 61 | male | 0 | 59 | 4.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.7 | false | MSS | 2026-03-15T05:36:00.676257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464192 | REC_0014181 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 7 | 64 | male | 1 | 16 | 6.5 | 6 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:36:00.676625+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879332 | REC_0014182 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 9 | 80 | female | 2 | 46 | 6.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 10 | true | MSS | 2026-03-15T05:36:00.676964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864928 | REC_0014183 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 13.1 | 57 | male | 0 | 6 | 5.6 | 3 | osimertinib 80 mg daily | 18.3 | true | MSI-H | 2026-03-15T05:36:00.677312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934568 | REC_0014184 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 11 | 11.1 | 63 | male | 1 | 19 | 7.3 | 8 | entrectinib 600 mg daily | 4 | false | MSI-H | 2026-03-15T05:36:00.677843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285924 | REC_0014185 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 6.1 | 72 | male | 1 | 10 | 6.7 | 2 | pembrolizumab 200 mg q3w | 16.3 | false | MSS | 2026-03-15T05:36:00.678238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_188052 | REC_0014186 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 10.1 | 67 | female | 1 | 12 | 6.3 | 5 | osimertinib 80 mg daily | 10.2 | true | MSS | 2026-03-15T05:36:00.678580+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243143 | REC_0014187 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 10 | 70 | female | 3 | 12 | 6 | 8 | entrectinib 600 mg daily | 13.8 | true | MSS | 2026-03-15T05:36:00.678906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835245 | REC_0014188 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 13.1 | 77 | male | 1 | 15 | 6.1 | 3 | osimertinib 80 mg daily | 9.2 | false | MSI-H | 2026-03-15T05:36:00.679262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825249 | REC_0014189 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 5.2 | 64 | female | 0 | 4 | 5.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.1 | false | MSS | 2026-03-15T05:36:00.679605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538828 | REC_0014190 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 33 | 10.4 | 64 | male | 0 | 4 | 6.9 | 2 | osimertinib 80 mg daily | 15.7 | true | MSS | 2026-03-15T05:36:00.679957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218083 | REC_0014191 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 14.8 | 67 | female | 0 | 10 | 7.1 | 3 | sotorasib 960 mg daily | 18.2 | false | MSI-H | 2026-03-15T05:36:00.680393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596630 | REC_0014192 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 17.3 | 68 | female | 0 | 21 | 4.1 | 1 | alectinib 600 mg BID | 14 | true | MSI-H | 2026-03-15T05:36:00.680809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603541 | REC_0014193 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 5.6 | 69 | female | 1 | 23 | 3.6 | 3 | pembrolizumab 200 mg q3w | 8.5 | true | MSS | 2026-03-15T05:36:00.681153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773204 | REC_0014194 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 11.6 | 87 | female | 2 | 4 | 5.4 | 1 | entrectinib 600 mg daily | 20.2 | false | MSI-H | 2026-03-15T05:36:00.681508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928377 | REC_0014195 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.6 | 61 | male | 1 | 70 | 6.6 | 7 | carboplatin + paclitaxel + pembrolizumab | 16.2 | true | MSS | 2026-03-15T05:36:00.681871+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_628911 | REC_0014196 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 6.2 | 67 | male | 0 | 11 | 5 | 8 | osimertinib 80 mg daily | 11.7 | false | MSS | 2026-03-15T05:36:00.682390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123478 | REC_0014197 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 8.6 | 74 | male | 2 | 9 | 5.4 | 7 | sotorasib 960 mg daily | 12.1 | false | MSS | 2026-03-15T05:36:00.682911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375523 | REC_0014198 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 7.3 | 73 | male | 1 | 19 | 5.3 | 8 | alectinib 600 mg BID | 12.2 | false | MSS | 2026-03-15T05:36:00.683275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485942 | REC_0014199 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.6 | 61 | female | 1 | 43 | 6.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 9 | false | MSS | 2026-03-15T05:36:00.683617+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_674459 | REC_0014200 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 5.9 | 74 | female | 2 | 6 | 5.2 | 5 | osimertinib 80 mg daily | 10.9 | true | MSS | 2026-03-15T05:36:00.683967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.